Cargando…

MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?

This review focuses on indeterminate lesions on prostate magnetic resonance imaging (MRI), assigned as PI-RADS category 3. The prevalence of PI-RADS 3 index lesion in the diagnostic work-up is significant, varying between one in three (32%) to one in five (22%) men, depending on patient cohort of fi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Schoots, Ivo G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861283/ https://www.ncbi.nlm.nih.gov/pubmed/29594022 http://dx.doi.org/10.21037/tau.2017.12.31

Ejemplares similares

Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies
por: Osses, Daniël F., et al.
Publicado: (2020)

Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions
por: Brancato, Valentina, et al.
Publicado: (2021)

Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies
por: Kortenbach, Karen-Cecilie, et al.
Publicado: (2022)

Living systematic review and meta-analysis of the prostate MRI diagnostic test with Prostate Imaging Reporting and Data System (PI-RADS) assessment for the detection of prostate cancer: study protocol
por: Oerther, Benedict, et al.
Publicado: (2022)

The Impact of Adding Digital Breast Tomosynthesis to BI-RADS Categorization of Mammographically Equivocal Breast Lesions
por: Hassan, Rania Mostafa, et al.
Publicado: (2023)

Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?
por: Schoots, Ivo G., et al.
Publicado: (2019)

Prostate MRI based on PI-RADS version 2: how we review and report
por: Steiger, Philipp, et al.
Publicado: (2016)

Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy
por: Yang, Shuo, et al.
Publicado: (2020)

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
por: Schoots, Ivo G., et al.
Publicado: (2018)

An Equivocal SCC Lesion—Antiepileptic-Induced CLOCC
por: Kuczyńska, Maryla, et al.
Publicado: (2022)

Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer
por: Rudolph, Madhuri M., et al.
Publicado: (2020)

The breast lesion excision system procedure: An optimal solution for the management of indeterminate BI-RADS category 3 breast lesions in women with severe anxiety
por: Hot, Semih, et al.
Publicado: (2018)

From PROMIS to PRO-MRI in primary prostate cancer diagnosis
por: Schoots, Ivo G., et al.
Publicado: (2017)

Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer
por: Khatri, Wajahat, et al.
Publicado: (2021)

Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report
por: Jia, Hanna, et al.
Publicado: (2022)

Delivering Clinical impacts of the MRI diagnostic pathway in prostate cancer diagnosis
por: Schoots, Ivo G., et al.
Publicado: (2020)

Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Lee, Chung-Un, et al.
Publicado: (2022)

Can a prostate biopsy be safely deferred on PI-RADS 1,2 or 3 lesions seen on pre-biopsy mp-MRI?
por: Abdul Raheem, Rickaz, et al.
Publicado: (2022)

The indeterminate adrenal lesion
por: Sahdev, Anju, et al.
Publicado: (2010)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [(68)Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
por: Zhao, Jing, et al.
Publicado: (2020)

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
por: Gomez-Gomez, Enrique, et al.
Publicado: (2021)

Machine Learning and Clinical-Radiological Characteristics for the Classification of Prostate Cancer in PI-RADS 3 Lesions
por: Gravina, Michela, et al.
Publicado: (2022)

Study of iron metabolism based on T2* mapping sequences in PI-RADS 3 prostate lesions
por: D, Wenhao, et al.
Publicado: (2023)

Detection of clinically significant prostate cancer with PI-RADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions
por: Westphalen, Antonio C., et al.
Publicado: (2019)

Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy
por: Wang, Yu-Hao, et al.
Publicado: (2023)

Insulinoma with equivocal imaging
por: Belabed, Wafa, et al.
Publicado: (2023)

ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology
por: Barbosa, Thayse Lozovoy Madsen, et al.
Publicado: (2019)

Indeterminate liver lesions in cancer
por: Robinson, P. J.
Publicado: (2015)

Indeterminate bone lesion: the diagnosis
por: Vanel, D., et al.
Publicado: (2015)

Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Natale, Caleb, et al.
Publicado: (2021)

The primacy of multiparametric MRI in men with suspected prostate cancer
por: Richenberg, Jonathan, et al.
Publicado: (2019)

Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions
por: Jin, Pengfei, et al.
Publicado: (2022)

In vivo multimodal optical imaging of dermoscopic equivocal melanocytic skin lesions
por: Elagin, V., et al.
Publicado: (2021)

Value of an online PI-RADS v2.1 score calculator for assessment of prostate MRI
por: Barth, Borna K., et al.
Publicado: (2021)

The added value of digital breast tomosynthesis in improving diagnostic performance of BI-RADS categorization of mammographically indeterminate breast lesions
por: Basha, Mohammad Abd Alkhalik, et al.
Publicado: (2020)

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions
por: Schoots, Ivo G., et al.
Publicado: (2019)

Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
por: Sauck, Anja, et al.
Publicado: (2022)

Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions
por: Li, Tianping, et al.
Publicado: (2022)

Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
por: Viana, Publio Cesar Cavalcanti, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_or9b2ss9dvmg721f5hsp7a2b4o